Document is current
Any future updates will be listed below
-
Authors
Liu, Tom
Fillbrunn, Mirko https://orcid.org/0000-0002-8037-703X
Zhang, Shiyuan https://orcid.org/0000-0001-8523-0419
Chen, Jingyi https://orcid.org/0009-0007-0141-2241
Li, Weilong
Platt, Julia
Niehoff, Nicole https://orcid.org/0000-0002-5852-3010
Sajeev, Gautam https://orcid.org/0000-0002-1827-8938
Signorovitch, James https://orcid.org/0000-0002-4067-8962
-
Funding
Funding for this research was provided by:
GSK plc
- License Information
-
More Information
Article History
Received: 4 December 2024
Accepted: 18 February 2025
First Online: 12 March 2025
Declarations
:
: This study was conducted according to GSK SOP52213 (Conducting Quality Control Review of Study Results generated using Existing Data in VEO and USVEO) and complied with all applicable laws regarding patient privacy. Clean, patient-level datasets were generated for analyses to ensure data integrity and to reformat raw data for all key study measures. All study results are presented as aggregate analyses that omit patient identification; therefore, informed consent and ethics committee or Institutional Review Board approval were not required.
: Tom Liu, Shiyuan Zhang, and Nicole Niehoff report employment with GSK. Nicole Niehoff reports stock/stock options from McKesson. Mirko Fillbrunn, Jingyi Chen, Weilong Li, Julia Platt, Gautam Sajeev, and James Signorovitch report employment with Analysis Group, which received funding support for this research from GSK. All authors acknowledge medical writing support for this manuscript, funded by GSK.
